BGM
HealthcareBGM Group Ltd.
$3.48
$-0.10 (-2.79%)
Jan 5, 2026
Price History (1Y)
Analysis
BGM Group Ltd. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company has a market capitalization of $698.17M and annual revenue of $29.87M, employing approximately 298 people. Financially, BGM Group Ltd.'s profitability metrics indicate significant losses, with a net income of -$7,861,673 and EBITDA of -$2,373,423 over the trailing twelve months. The company's operating margin stands at -5.4%, while its profit margin is -26.3%. In terms of returns, BGM Group Ltd. reported a return on equity (ROE) of -16.5% and a return on assets (ROA) of -3.8%. On the balance sheet side, the company has $100,756 in debt against cash reserves of $25.36M, resulting in a debt-to-equity ratio of 0.22. BGM Group Ltd.'s valuation metrics are marked by significant price to sales and price to book ratios, at 23.37 and 1.88 respectively. The company's revenue growth has been negative over the past year, with a decline of -56.9%. There is no dividend payout or yield information available for BGM Group Ltd.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BGM Group Ltd.
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Visit website →Key Statistics
- Market Cap
- $698.17M
- P/E Ratio
- N/A
- 52-Week High
- $17.17
- 52-Week Low
- $3.25
- Avg Volume
- 18.03K
- Beta
- 1.46
Company Info
- Exchange
- NCM
- Country
- China
- Employees
- 298